Scholarlink

Objective <p>To evaluate the predictive value of the mean platelet volume–to–albumin (MPV/Alb) ratio for pathological complete response (pCR) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) treated with neoadjuvant chemotherapy (NACT).</p> Methods <p>In this retrospective single-center study, 139 consecutive patients with HER2-positive breast cancer who received dual anti-HER2 therapy combined with anthracycline- and taxane-based neoadjuvant chemotherapy between December 2022 and February 2025 were included. Clinicopathological variables, immuno-inflammatory parameters, and the MPV/Alb ratio were analyzed. Predictors of pCR were assessed using univariable and multivariable logistic regression. Discriminative performance and an optimal cut-off for MPV/Alb were determined by receiver operating characteristic (ROC) analysis.</p> Results <p>The median age was 50 years (range, 26–79), and pCR was achieved in 54.7% of patients. On univariable analyses, estrogen receptor (ER) status, progesterone receptor (PR) status, and MPV/Alb were associated with pCR. In multivariable analysis, only MPV/Alb remained an independent predictor of pCR (<i>p</i> = 0.012; odds ratio [OR], 0.388; 95% confidence interval [CI], 0.185–0.813). ROC analysis identified an optimal MPV/Alb cutoff of 2.32 (AUC 0.626; 95% CI 0.535–0.720; <i>p</i> = 0.048), yielding 64.5% sensitivity and 58.7% specificity.</p> Conclusions <p>The MPV/Alb ratio may serve as an independent predictor of pCR in HER2-positive BC undergoing NACT. As a readily obtainable, low-cost composite derived from routine laboratory tests, MPV/Alb could aid risk stratification and treatment decision-making in clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mean platelet volume-to-albumin ratio as a predictor of pathological complete response in HER2-positive breast cancer undergoing neoadjuvant chemotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月14日

查看全文
  • Hatice Ayyıldız Sevim,
  • Mehmetcan Atak,
  • Zeynep Altundağ Derin,
  • Selahattin Çelik,
  • İsmail Burak Gültekin,
  • Doğan Yazılıtaş

摘要

Objective

To evaluate the predictive value of the mean platelet volume–to–albumin (MPV/Alb) ratio for pathological complete response (pCR) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) treated with neoadjuvant chemotherapy (NACT).

Methods

In this retrospective single-center study, 139 consecutive patients with HER2-positive breast cancer who received dual anti-HER2 therapy combined with anthracycline- and taxane-based neoadjuvant chemotherapy between December 2022 and February 2025 were included. Clinicopathological variables, immuno-inflammatory parameters, and the MPV/Alb ratio were analyzed. Predictors of pCR were assessed using univariable and multivariable logistic regression. Discriminative performance and an optimal cut-off for MPV/Alb were determined by receiver operating characteristic (ROC) analysis.

Results

The median age was 50 years (range, 26–79), and pCR was achieved in 54.7% of patients. On univariable analyses, estrogen receptor (ER) status, progesterone receptor (PR) status, and MPV/Alb were associated with pCR. In multivariable analysis, only MPV/Alb remained an independent predictor of pCR (p = 0.012; odds ratio [OR], 0.388; 95% confidence interval [CI], 0.185–0.813). ROC analysis identified an optimal MPV/Alb cutoff of 2.32 (AUC 0.626; 95% CI 0.535–0.720; p = 0.048), yielding 64.5% sensitivity and 58.7% specificity.

Conclusions

The MPV/Alb ratio may serve as an independent predictor of pCR in HER2-positive BC undergoing NACT. As a readily obtainable, low-cost composite derived from routine laboratory tests, MPV/Alb could aid risk stratification and treatment decision-making in clinical practice.